Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Scutellaria baicalensis (Baicalin).
A flavone glycoside that modulates GABA-A receptors and inhibits pro-inflammatory cytokines via NF-κB pathway suppression, primarily utilized for neuroprotection and systemic anti-inflammatory applications.
5281605
270.24 g/mol
1.7
5,6,7-trihydroxy-2-phenylchromen-4-one
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Scutellaria baicalensis (Baicalin) across standard consumer modalities.
The high hygroscopicity of concentrated Scutellaria extracts necessitates the use of moisture-resistant excipients to prevent powder clumping and chemical degradation.
The intense bitter profile and strong yellow pigment of baicalin pose significant challenges for flavor masking and maintaining aesthetic consistency in pectin-based matrices.
Low aqueous solubility and high therapeutic dose requirements typically exceed the 20-40mg payload capacity of standard thin-film polymer matrices.
Ready to launch a product featuring Scutellaria baicalensis (Baicalin)? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Scutellaria baicalensis (Baicalin) extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Scutellaria baicalensis (Baicalin) payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation